Medical outpatient sales jump 21% as portfolio premium widens

Medical outpatient buildings (MOBs) are catching the bid that has been bypassing traditional office. Cushman & Wakefield counted $6.7 billion in MOB investment sales in the first half of 2026. That total is up 21% from the same period a year earlier. Connect CRE carried the data.

The cap rate on MOB transactions fell 35 basis points year over year. It now sits at 6.8%. Average asset pricing reached $368 per square foot in the second quarter. Both numbers say the bid is expanding, not just stabilizing. Cushman & Wakefield credits improving capital market conditions, expanding lender appetite, and resilient operating fundamentals. The same trio has been reopening other property types this year.

The portfolio side tells a more aggressive story. Portfolio transaction volume exceeded $2.6 billion in the first half. That is more than double the year-earlier pace. The premium buyers pay for portfolios over single assets widened to a full percentage point. A buyer stepping up in size is surrendering that much yield. It is not a rounding error; it is institutional capital paying for diversification and the ability to deploy large checks in a sector still built around 50,000-square-foot buildings.

Sandy Romero, Cushman & Wakefield's head of office and alternatives research, attributes the surge to cap rate compression, renewed debt market liquidity, and rising portfolio demand. "With capital becoming more readily available, we expect MOBs to remain well-positioned to attract institutional investment through the balance of 2026," she said in the report.

Lender appetite is part of the explanation. Cushman & Wakefield lists renewed debt market liquidity as one of the three forces behind the volume jump. This publication has seen the same pattern across other sectors: lenders will finance property types with steady demand and stay cautious on speculative office. MOBs fit that profile, and the debt market is now treating them accordingly.

Part of the jump reflects a weak comparison base. First-half 2025 trades were slow as the rate cycle kept buyers and sellers apart. A 21% gain on top of that is partly a rebound. The portfolio number more than doubled, so rebound does not explain it. That is a change in the buying pool — institutions are moving from testing single deals to assembling whole platforms.

The MOB data fits the recovery visible across property types, and that recovery runs on more than data centers. Construction starts have slowed in office, industrial, and apartment markets, giving owners leverage even as lenders return. Medical outpatient buildings are a smaller slice of the same trend; the money moving into them reflects the search for assets with recurring income.

MOBs have been bucketed with office in every distress story for two years, but the cap rate direction says the shorthand is wrong. Office distress is still filling news feeds; MOB cap rates are compressing. The tenant base is likely the difference: doctors' offices and outpatient centers renew leases because they cannot relocate a practice easily, and health systems are expanding outpatient capacity. None of that is in the Cushman & Wakefield data as a line item, but it is the obvious explanation for why rent growth stays steady and occupancy stays high.

The portfolio premium is the number allocators should watch. A 6.8% cap rate on a single building sounds like yield. Apply the 100-basis-point discount for scale. A diversified MOB portfolio then clears at roughly 5.8%. The spread is the market's own estimate of the risk in going it alone. We think that spread is too narrow. A portfolio spreads lease rolls across dozens of properties and health systems; a single asset carries one roof, one tenant type, one local health-care market.

The next leg of this recovery will reward scale. Allocators backing MOBs are better off in portfolio positions than in single-asset purchases right now. As cap rates keep compressing, the single-asset buyer is left paying peak pricing for a building that behaves like a bond with a hospital's balance sheet behind it. The portfolio buyer is the one redeeming the yield. Second-half data will show whether volume holds; the portfolio premium is the first line to watch.